Soleno Therapeutics: Safety Concerns May Undermine Launch (NASDAQ:SLNO)
Soleno Therapeutics(US:SLNO) Seeking Alphaยท2025-09-17 19:57Group 1 - Soleno Therapeutics (NASDAQ: SLNO) recently received approval for its drug Vykat (diazoxide choline) aimed at treating patients over 4 years old with Prader-Willi syndrome [1] - The article promotes a weekly newsletter that provides insights into stocks in the biotech, pharma, and healthcare sectors, highlighting key trends and catalysts that influence market valuations [1] - The investing group Haggerston BioHealth, led by a biotech consultant with over 5 years of experience, offers detailed reports on more than 1,000 companies, including sales forecasts and financial analyses [1]